J&J's Tremfya shows fistula remission in Crohn's subgroups

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. COF
7. GOOGL
8. RTX
9. TSLA
10. META

Go back to J&J's Tremfya shows fistula remission in Crohn's subgroups

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

October 12, 2026 4:05 PM EDT

New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years

SPRING HOUSE, Pa., Oct. 12, 2026 /PRNewswire/ --... More